Rates of serious infectious events and opportunistic infections in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with etanercept or placebo in clinical trials

被引：0
|
作者：
Hamza, S. [1 ]
Chon, Y. [1 ]
Hooper, M. [1 ]
MacPeek, D. [2 ]
Lin, S. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Wyeth Pharmaceut, Collegeville, Philadelphia, PA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [31] Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
    Andrea Rubbert-Roth
    Adriana M. Kakehasi
    Tsutomu Takeuchi
    Marc Schmalzing
    Hannah Palac
    Derek Coombs
    Jianzhong Liu
    Samuel I. Anyanwu
    Ralph Lippe
    Jeffrey R. Curtis
    Rheumatology and Therapy, 2024, 11 : 97 - 112
  • [32] Effect of Tofacitinib on Reducing Pain in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
    Ogdie, Alexis
    de Vlam, Kurt
    McInnes, Iain B.
    Mease, Philip J.
    Baer, Philip
    Lukic, Tatjana
    Kwok, Kenneth
    Wang, Cunshan
    Hsu, Ming-Ann
    Maniccia, Anna
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [33] Rates of serious infections from adalimumab (HUMIRA®) clinical trials of patients with Rheumatoid Arthritis (RA)
    Kent, J. D.
    Pangan, A. L.
    Spencer-Green, G. T.
    Szczerbak, N.
    Sasso, E. H.
    RHEUMATOLOGY, 2006, 45 : I42 - I43
  • [34] Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients
    Borras-Blasco, Joaquin
    Gracia-Perez, Antonio
    Dolores Rosique-Robles, J.
    Elvira Castera, M. D.
    Javier Abad, F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (02) : 145 - 150
  • [35] Serious infection rates remain stable in patients with rheumatoid arthritis treated with adalimumab in clinical trials
    Kent, J
    Pangan, A
    Sasso, E
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB207 - AB207
  • [36] POOLED ANALYSIS OF THE RISK OF SERIOUS INFECTIONS AND OPPORTUNISTIC INFECTIONS IN CLINICAL TRIALS OF CERTOLIZUMAB PEGOL FOR RHEUMATOID ARTHRITIS
    Mariette, X.
    Bertin, P.
    Arendt, C.
    Terpstra, I.
    VanLunen, B.
    de Longueville, M.
    RHEUMATOLOGY, 2012, 51 : 132 - 132
  • [37] Health-related quality of life in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with certolizumab pegol
    Sarobe, Maite
    Arrondo, Amaya
    Ibarrondo, Oliver
    Mar, Javier
    FARMACIA HOSPITALARIA, 2022, 46 (01) : 27 - 30
  • [38] Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study
    Rotar, Ziga
    Svetina, Petra
    Tomsic, Matija
    Hocevar, Alojzija
    Prapotnik, Sonja
    BMJ OPEN, 2020, 10 (02):
  • [39] Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Kay, Jonathan
    Fleischmann, Roy
    Keystone, Edward
    Hsia, Elizabeth C.
    Hsu, Benjamin
    Zhou, Yiying
    Goldstein, Neil
    Braun, Juergen
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (12) : 2120 - 2130
  • [40] Duration Of Symptoms Before Diagnosis In Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis.
    Hetland, Merete Lund
    Sorensen, Jan
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S42 - S43
12345